

Michelle L Irvin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/340778/publications.pdf>

Version: 2024-02-01

15
papers

713
citations

933447

10
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

1016
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis and evaluation of 2- α -dihalo ribonucleotide prodrugs with activity against hepatitis C virus. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115208.	3.0	3
2	Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126986.	2.2	5
3	Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1078-1088.	2.0	4
4	Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	38
5	Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir. <i>Journal of Medical Virology</i> , 2018, 90, 109-119.	5.0	13
6	<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	74
7	Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir. <i>PLoS ONE</i> , 2018, 13, e0205186.	2.5	9
8	Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection. <i>Viruses</i> , 2018, 10, 462.	3.3	2
9	Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	62
10	<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	117
11	Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5445-5454.	3.2	96
12	<i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 988-997.	3.2	108
13	<i>In Vitro</i> Activity and Resistance Profile of Dasabuvir, a Nonnucleoside Hepatitis C Virus Polymerase Inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1505-1511.	3.2	109
14	Phenotypic Analysis of T-Cells in Extensive Alopecia Areata Scalp Suggests Partial Tolerance. <i>Journal of Investigative Dermatology</i> , 2006, 126, 366-373.	0.7	19
15	Granulocyte-Macrophage Colony-Stimulating Factor Priming plus Papillomavirus E6 DNA Vaccination: Effects on Papilloma Formation and Regression in the Cottontail Rabbit Papillomavirus-Rabbit Model. <i>Journal of Virology</i> , 2000, 74, 8700-8708.	3.4	54